INTRODUCTION
A V A R IETY O F cancer gene therapies have been developed and proven effective against experimental tumors in vivo. For a given cancer gene therapy to be clinically successful, however, it must selectively destroy malignant cells while minimizing damage to normal tissue. One approach that has proven effective at increasing the differential response between tumor and normal tissue is suicide gene therapy. Suicide gene therapy involves the tumor-targeted delivery of genes encoding metabolic enzymes that convert systemically delivered, innocuous prodrugs into toxic metabolites. This results in a high concentration of toxic product intratumorally, thereby avoiding the system ic toxicity often associated with conventional chemotherapy (e.g., 5-fluorouracil ). Two suicide gene systems that have been studied intensely are herpes simplex type 1 thym idine kinase (HSV-1 TK)/ganciclovir (GCV) and Escherichia coli cytosine deaminase (CD)/5-fluorocytosine (5-FC). HSV-1 TK phosphorylates GCV, converting it to a nucleotide analog Departments of Radiation Oncology and Molecular Biology, Henry Ford Health System, Detroit, MI 48202.
that inhibits DNA synthesis (DeClercq, 1984) , while CD converts 5-FC to its highly toxic metabolite, 5-FU (Calabresi and Chabner, 1990) .
Effective cancer gene therapy also requires an efficient and reproducible method of in vivo gene delivery. Currently, recom binant adenoviruses represent the most efficient means of delivering genes to solid tumors. Preclinical studies have dem onstrated a high efficiency of gene transfer and effective tumor control after regional delivery of replication-defect ive, CD-or HSV-1 TK-containing adenoviruses, coupled with 5-FC or GCV therapy (Chen et al., 1994; Hirschowitz et al., 1995; Dong et al., 1996; Eastman et al., 1996; Ohwada et al., 1996; Block et al., 1997; Evoy et al., 1997; Hall et al., 1997; Sutton et al., 1997) .
In an attempt to improve the efficacy of these monotherapies, we previously coupled the CD/5-FC and HSV-1 TK/GCV enzyme/prodrug systems and pioneered the concept of using them as a neoadjuvant to radiation therapy (Kim et al., 1994 (Kim et al., , 1995 (Kim et al., , 1997 Khil et al., 1996; Rogulski et al., 1997a,b; Freytag et al., 1998; Gable et al., 1998) . We used a CD/HSV-1 TK fusion gene to demonstrate that double suicide gene therapy is markedly more efficacious than either single gene therapy (Rogulski et al., 1997a,b) . Moreover, when used as a neoadjuvant to radiation therapy, double suicide gene therapy sensitized tum ors to the toxic effects of radiation (i.e., radiosensitization), resulting in markedly better tum or control and cure. On the basis of these findings, we believe that double suicide gene therapy, when used as a neoadjuvant to radiation therapy, will demonstrate efficacy in the clinic provided that the CD/HSV-1 TK fusion gene can be delivered efficiently and selectively to the tum or site.
In an attempt to increase the efficiency of gene expression and delivery, we developed a replication-com petent adenovirus (Ad5-CD/TKrep) containing the CD/HSV-1 TK fusion gene (previously called FGR; Freytag et al., 1998) . The replicative capacity of the Ad5-CD/TKrep virus results in much greater (up to 2000-fold) transgene expression per cell relative to replication-defective adenoviruses and has the potential to improve the gene transduction efficiency (percentage of tumor cells infected) via viral spread. Moreover, because Ad5-CD/TKrep is cytolytic, the virus itself provides a powerful therapeutic modality that is not possible with replicationdefective adenoviruses. Ad5-CD/TKrep effectively destroyed tumor cells in vitro while displaying minim al cytotoxicity toward normal cells . Moreover, both the CD/5-FC and HSV-1 TK/GCV suicide gene systems augmented the tum or cell-specific cytopathic effects of the Ad5-CD/TKrep virus and sensitized tum or cells to radiation. We have now extended these in vitro findings in vivo by demonstrating that double suicide gene therapy augments significantly the antitumor activity of Ad5-CD/TKrep and that both modalities, when combined, are an effective neoadjuvant to radiation therapy.
MATERIALS AND METHODS

Cell lines and recombinant adenoviral vectors
C33A cells, obtained from American Type Culture Collection (ATCC, Rockville, MD), were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and nonessential amino acids. The construction and generation of the E1B-attenuated , replicationcom petent Ad5-CD/TKrep adenovirus (previously called FGR) and its replication-defecti ve counterpart, Ad5-FGNR (previously called Ad5-CDgly TK), have been described previously . The names of the viruses were changed per the recomm endation of the Food and Drug Administration (FDA). Adenoviral titers were determined by plaque assay, using HEK293 cells (Graham and Prevec, 1991) , and are expressed as plaque-forming units (PFU).
Prodrug sensitivity assays
Cells (5 3 10 5 /60-mm dish) were either mock infected or infected with Ad5-FGNR at a multiplicity of infection (MOI) of 100 in 1 ml of DMEM with 2% FBS. After 1 hr, cells were replated (1.5 3 10 4 cells/well, 24-well plate) in DMEM containing 10% FBS (growth medium). Seventy-two hours postinfection, the medium was removed and replaced with fresh medium without or with 5-FC (Sigma, St. Louis, MD) or GCV (Syntex, Palo Alto, CA). Cells were cultured in the presence of prodrugs for 96 hr. Cell viability was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide; Sigma] assay according to the manufacturer protocol.
Ad5-CD/TKrep viral replication in the presence of prodrugs
C33A cells (10 6 /60-mm dish) were either mock infected or infected with Ad5-CD/TKrep at an MOI of 10 in 0.2 ml of DMEM with 2% FBS. After 1 hr, the medium was removed and cells were immediately replated (2 3 10 4 cells/well, 24-well plate) in varying concentrations of 5-FC or GCV. Low molecular weight DNA was isolated 48 hr postinfection and analyzed by Southern blotting as previously described .
In vivo adenovirus-mediated suidide gene therapy
Five-to 6-week-old female athymic mice (nu/nu [CD-1]; Charles River Laboratories, Wilmington, MA) were used in all studies. C33A tumors were established by inoculating 2 3 10 6 cells prepared in 0.9% NaCl and 15% Matrigel (Collaborative Biomedical Products, Bedford, MA), subcutaneously over the abdomen or intram uscularly within the right gastrocnemius muscle. On reaching 100 mm 3 (subcutaneous) or 120 mm 3 (intramuscular), tumors were injected with 10 8 PFU of Ad5-CD/TKrep or phosphate-buffere d saline (PBS, 50 m l) for five consecutive days (days 0-4). Daily injections were distributed evenly throughout the tumor. At the conclusion of the viral inoculations, mice in the prodrug treatment groups received intraperitoneal injections of 5-FC (500 mg/kg), GCV (60 mg/kg), or 5-FC (500 mg/kg) 1 GCV (60 mg/kg). Prodrugs were administered daily as indicated in Figs. 1 and 3. Tumors were measured every 2-3 days. Tumor volume was determined by three-dimension al caliper measurements .
Radiation therapy
As detailed above, C33A cells were implanted into the right gastrocnemius muscle. Intramuscular, rather than subcutaneous, tumors are used to minimize stretching of the skin, which can lead to unacceptable ulceration after irradiation. When tumors reached 120 mm 3 , animals received five daily intratum oral injections of Ad5-CD /TKrep or PBS (days 0-4). After the last viral injection (day 4), Ad5-CD/TKrep-treated mice were divided into two groups (Ad5-CD/TKrep, Ad5-CD/TKrep 1 5-FC 1 GCV; 10 animals per group). Prodrug-treated animals received daily injections of 5-FC (500 mg/kg) and GCV (60 mg/kg) for either 4 or 7 days, as indicated in Figs. 1 and 3 , beginning on day 4. On the day of irradiation, the two treatment groups were further subdivided into four groups (five animals per group) based on comparable tumor volumes: Ad5-CD/TKrep, Ad5-CD/TKrep 1 radiation treatm ent (RT), Ad5-CD/TKrep 1 5-FC 1 GCV, and Ad5-CD/TKrep 1 5-FC 1 GCV 1 RT. Radiation was delivered to the tumored leg 2 hr after prodrugs were given for that day. For radiation response controls, five uninjected tumors with volumes comparable to those within the Ad5-CD/TKrep 1 RT and Ad5-CD/TKrep 1 5-FC 1 GCV 1 RT groups were also irradiated. Animals in the radiation treatment groups were anesthetized by intraperitoneal injection of Nembutal (60 mg/kg) and a single dose of 60 Co gradiation (8 or 10 Gy) was delivered to the tum or-bearing leg as described previously (Rogulski et al., 1997b) . Volum es of intramuscular leg tumors were determ ined by the follow ing formula (Alfieri and Hahn, 1978) : d9 3 2 (0.6) 2 d9 5 volum e (cm 3 ), where d9 is the average diameter of the tum ored leg (cm) and the product (0.6) 2 d9 is the correction factor for nomal leg volume. For all tumor studies, animals were followed until death (euthanasia) from tum or burden or for at least 90 days after cessation of treatment. All animal experiments were approved by the Care of Experimental Animal Committee of Henry Ford Hospital (Detroit, MI). An extensive toxicology study has been com pleted with the Ad5-CD/TKrep virus without and with double prodrug therapy after intraprostatic administration in C57BL/6 mice. The results of these studies will be made available to any investigator on request.
RESULTS
Double suicide gene therapy augments the antitumor activity of the replication-competent Ad5-CD/TKrep adenovirus
The therapeutic efficacy of the CD/5-FC and HSV-1 TK/GCV suicide gene systems in the context of the replicationcom petent Ad5-CD/TKrep adenovirus was evaluated using the hum an C33A (cervical carcinom a) tumor xenograft. Subcutaneous abdominal tumors (100 mm 3 ) were injected with either PBS or Ad5-CD/TKrep (10 8 PFU) for five consecutive days. As both suicide gene systems were previously demonstrated to interfere with Ad5-CD/TKrep replication , prodrug therapy commenced shortly after completion of viral inoculation to allow for viral replication and spread. In initial studies, prodrug therapy was continued until tumors stopped regressing (, 3 weeks).
Intratumoral inoculation of Ad5-CD/TKrep itself resulted in a significant tumor growth delay of 25 days (p 5 0.015; ANOVA relative to PBS-injected controls (Fig. 1A) . This was not a nonspecific effect of adenoviral injection, as parallel tumors injected with a replication-defective version of Ad5-CD/TKrep, Ad5-FGNR , resulted in a tumor growth delay (7 days) that was not significantly different from the control group (Fig. 1A) . Thus, as expected, Ad5-CD/TKrep itself, via its cytolytic activity, provides significant tumor control. The efficacy of Ad5-CD/TKrep viral therapy was markedly enhanced by double suicide gene therapy. On day 23, when Ad5-CD/TKrep-treated tumors averaged , 125 mm 3 , those treated with Ad5-CD/TKrep viral and double prodrug therapies averaged only , 8 mm 3 , representing a 94% reduction in volume relative to Ad5-CD/TKrep viral therapy alone. The combination of Ad5-CD/TKrep viral and double prodrug therapies resulted in a tumor growth delay of 66 days relative to PBS-injected controls, which was significantly greater (p 5 0.011; ANOVA) than Ad5-CD/TKrep therapy alone (Table 1) . Importantly, no toxicity (animal death or sustained weight loss) was observed after Ad5-CD/TKrep viral and double prodrug therapies.
To determ ine whether the dramatic augmentation of Ad5-CD/TKrep viral therapy by double prodrug therapy was attributable predominantly to one of the suicide gene systems, the effects of com bining Ad5-CD/TKrep viral therapy with 5-FC or GCV prodrug therapy independently were also examined. As pilot studies demonstrated that extending the prodrug therapy regimen beyond 7 days did not result in significantly better tumor control (our unpublished results, 1999), a 7-day prodrug therapy regimen was adopted in subsequent experiments. As was observed with the 21-day prodrug therapy regimen ( Fig.  1A ), 7 days of double prodrug therapy (Fig. 1B ) resulted in rapid tumor regression, ultimately yielding a tum or growth delay of 67 days, which was more than three times that (20 days) of Ad5-CD/TKrep viral therapy alone (Table 1) . These results dem onstrate the reproducibility of the double prodrug therapy effect, which was observed in eight independent experiments. In marked contrast to double suicide gene therapy, neither the CD/5-FC nor HSV-1 TK/GCV system significantly (p $ 0.2; ANOVA) improved tum or control beyond that of Ad5-CD/TKrep viral therapy alone. 5-FC therapy produced a mild, transient enhancement of the Ad5-CD /TKrep viral effect, which, in contrast with double prodrug therapy, was rapidly lost on com pletion of the prodrug therapy course (Fig. 1B) . GCV therapy resulted in tumor growth kinetics that were essentially identical to those of Ad5-CD/TKrep itself (Fig. 1B) . These results demonstrate clearly that in the context of a replicationcom petent adenovirus, double suicide gene therapy is therapeutically superior to single suicide gene therapy and corroborate our previous findings with retrovirally transduced tumor lines (Rogulski et al., 1997b) .
The marked enhancement of Ad5-CD/TKrep viral therapy by double prodrug therapy, despite the relative impotence of the individual suicide gene system s, suggests synergistic interactions between the CD/5-FC and HSV-1 TK/GCV systems, which have been docum ented previously (Rogulski et al., 1997a,b; Aghi et al., 1998; Uckert et al., 1998) . The failure of either suicide gene system to independently augment the antitumor effects of the Ad5-CD/TKrep virus could derive from an inherent insensitivity ot C33A tum or cells to the individual prodrugs, or a balance between suicide gene-mediated cytotoxicity and inhibition of Ad5-CD/TKrep viral replication . To discern between these two possibilities, the suicide gene-mediated effects were examined in vitro. For pro-drug sensitivity assays, C33A cells were infected with Ad5-FGNR, a replication-defect ive version of Ad5-CD/TKrep , allowing suicide gene-mediated cytotoxicity to be analyzed independently from Ad5-CD/TKrep viral cytopathicity. Ad5-FGNR-infected C33A cells were sensitive to both 5-FC and GCV in a concentration-depe ndent manner, making it unlikely that the failure of these prodrugs to enhance the Ad5-CD/TKrep viral effect in vivo was due to an inherent insensitivity of C33A tumors to the prodrugs ( Fig. 2A) . Analysis of Ad5-CD/TKrep replication in C33A cells revealed that the HSV-1 TK/GCV system was effective at inhibiting viral replication (Fig. 2B) . Indeed, the concentration of GCV required to com pletely inhibit Ad5-CD/TKrep viral replication in vitro (0.2 m g/ml or 0.8 m M) is below that obtainable in humans (2-30 m M) when using lower doses (15 mg/kg/day) of GCV.
The CD/5-FC system inhibited Ad5-CD/TKrep viral replica- b Animals were given daily intraperitoneal injections of 5-FC (500 mg/kg), GCV (60 mg/kg), or 5-FC (500 mg/kg) 1 GCV (60 mg/kg) for either 21 or 7 days as indicated. (100 mm 3 ) were injected with PBS or 10 8 PFU of Ad5-FGNR or Ad5-CD/TKrep virus for five consecutive days (days 0-4, solid bar). Two days after the last virus injection (day 6), Ad5-CD /TKrep-injected animals were either left untreated or administered 5-FC (500 mg/kg) and GCV (60 mg/kg) for 21 consecutive days (days 6-26, hatched bar). The dotted line represents the predetermined end point of 400 mm 3 . Each group contained five animals. (B) Subcutaneous abdom inal C33A tumors (100 mm 3 ) were injected with either PBS or 10 8 PFU of Ad5-CD/TKrep virus for five consecutive days (days 0-4, solid bar). Virus-injected animals were either left untreated or adm inistered 5-FC (500 mg/kg), GCV (60 mg/kg), or 5-FC (500 mg/kg) and GCV (60 mg/kg) for seven consecutive days (days 6-12, hatched bar). Each group contained five animals. In this experiment only, the biological end point of 400 mm 3 could not be used as one animal within the double prodrug treatment group developed a large secondary tumor and had to be euthanized before the mean tumor volume of the group attained 400 mm 3 . Thus, tumor growth delays were determined by using 200 mm 4 as the end point. Note that this probably underestimates the tumor grow th delay of the double prodrug therapy group as the tum or growth rate of this group, after treatment, was slower than that of the other groups.
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tion only at the highest concentration examined (100 m g/ml or , 0.8 mM), which is well below the mean serum concentration (3.8 mM) obtainable in mice with this dose (500 mg/kg/day) of 5-FC (Huber et al., 1993) . Cumulatively , the in vitro analyses suggest that the failure of either suicide gene system to independently enhance the antitum or effects of the Ad5-CD/TKrep virus likely results from a balance betw een suicide gene-mediated cytotoxicity and inhibition of viral replication. Nevertheless, it is clear that despite the effects of these suicide gene systems on Ad5-CD/TKrep viral replication, when used concom itantly, they improve dramatically the efficacy of Ad5-CD/TKrep viral therapy in vitro. 
B Potentiation of radiotherapy by Ad5-CD/TKrepmediated double suicide gene therapy
Using retrovirally transduced, radioresistant tumor lines stably expressing the CD/HSV-1 TK fusion gene, we dem onstrated previously that both the CD/5-FC and HSV-1 TK/GCV systems can sensitize tumor cells to the toxic effects of radiation (Kim et al., 1994 (Kim et al., , 1995 (Kim et al., , 1997 Khil et al., 1996; Rogulski et al., 1997a; Freytag et al., 1998; Gable et al., 1998) . Even greater radiosensitization is achieved when both enzym e/prodrug systems are used simultaneously (Rogulski et al., 1997a,b; . To assess the full potential of the trimodal (viral, suicide gene, radiation) approach, Ad5-CD/TKrep-mediated double suicide gene therapy was used as a neoadjuvant to radiation therapy. Each single and dual modality was also evaluated to determ ine the contribution of each therapeutic arm. Because the radiation studies require that the body be shielded during irradiation, C33A cells were inoculated intram uscularly into the leg. After administration of the Ad5-CD /TKrep virus, half of the animals received double prodrug therapy (days 4-10). Animals within the radiation treatment groups received a single dose of g radiation to the tumored leg midway through the prodrug course.
As observed in the subcutaneous model ( Fig. 1A and B ), Ad5-CD/TKrep viral therapy alone resulted in a significant (p 5 0.0037; ANOVA) tumor growth delay of 29 days relative to PBSinjected controls and 40% tumor cure (Fig. 3A, Table 2 ). Notably, with respect to tumor cure rate, Ad5-CD/TKrep viral therapy was equivalent to 10 Gy of radiation, which demonstrates clearly the benefit of using a cytolytic adenovirus as a gene therapy vector (i.e., injection of the replication-defective Ad5-FGNR virus yields no tumor cure; our unpublished results, 1999). As expected, the addition of 7 days of double prodrug therapy markedly enhanced both the tumor growth delay and cure rate of Ad5-CD/TKrep viral therapy in the intramuscular model. Whereas Ad5-CD/TKrep viral therapy itself resulted in an average tumor growth delay of 29 days and 40% cure, Ad5-CD/TKrep viral and double prodrug therapies produced a tumor growth delay of at least 100 days and 80% cure (Fig. 3A , Table  2 ). The basis for the greater efficacy observed in the intramuscular model (tumor growth delay . 100 days) relative to that achieved in the subcutaneous model (tumor growth delay . 67 days) is unclear, but may be due to better tumor vascularization resulting in more efficient prodrug delivery.
The trimodal Ad5-CD/TKrep viral, double suicide gene, and radiotherapy approach resulted in significant tum or regression, but ultimately produced the same tumor grow th delay (. . 100 days) and high cure rate (80%) as the combination of Ad5-CD/TKrep viral and double prodrug therapies (Fig. 3A , Table  2 ). Because the combination of Ad5-CD/TKrep viral and double suicide gene therapies was so effective in this regimen, likely masking any radiosensitization effect, these studies were repeated with an abbreviated prodrug therapy course (4 versus 7 days) and a lower dose of radiation (8 versus 10 Gy). 
A B
Independently, Ad5-CD/TKrep viral and radiation therapy (8 Gy) each resulted in an average tum or growth delay of 42-45 days and 40 and 20% tumor cure, respectively (Fig. 3B , Table  3 ). In contrast to the 7-day prodrug therapy regimen (Fig. 3A) , the abbreviated 4-day regimen produced only a transient enhancem ent of the Ad5-C D/TKrep viral effect without improving therapeutic outcom e, yielding an average tumor growth delay and cure rate (40% ) identical to that of Ad5-CD/TKrep viral therapy alone (Fig. 3B, Table 3 ). These results dem onstrate the critical importance of the length of the prodrug therapy regimen (4 days-same outcom e as Ad5-CD/TKrep viral therapy; 7 days-markedly better outcom e than Ad5-CD/TKrep viral therapy). A profound antitumor effect resulted when com bining Ad5-CD /TKrep viral, double suicide gene, and radiation therapies (trimodal therapy). Rapid tumor regression occurred shortly after radiation therapy (Fig. 3B) . On day 18, when tumors within all other treatment groups averaged between 40 to 180% of their pretreatment volumes, those within the trimodal therapy group were apparently eradicated. Trimodal therapy resulted in a tum or growth delay of at least 100 days a high cure rate (80%), which was much greater than that achieved with any other monotherapy or dual therapy. Such results were obtained in two independent experiments. The one animal in the trimodal therapy group that was not cured 90 days posttreatment (60-mm 3 tumor) became tumor free at 6 months, ultimately yielding a cure rate of 100% . Thus, whereby shortening the prodrug therapy course to 4 days essentially eliminated the chemotherapeuti c effect of double prodrug therapy, the suicide gene-mediated radiosensitization effect remained. The results dem onstrate that double suicide gene therapy, in the context of the replication-comp etent Ad5-CD/TKrep adenovirus, is an effective neoadjuvant to radiation therapy.
DISCUSSION
We demonstrated previously in vitro the potential of the trimodal approach of Ad5-CD/TKrep viral, double suicide gene, and radiation therapies. We now dem onstrate in vivo that double suicide gene therapy significantly enhances the antitumor activity of the replication-com petent Ad5-CD/TKrep adenovirus and that these modalities, when combined, are an effective neoadjuvant to radiation therapy. Given that 50% of all human cancer patients are treated with radiation, it is possible that Ad5-CD/TKrep viral and double suicide gene therapies will dem onstrate value in the clinic.
As demonstrated originally by us (Rogulski et al., 1997a,b; Kim et al., 1998) and confirm ed subsequently by others (Aghi et al., 1998; Uckert et al., 1998) , double suicide gene therapy is therapeutically superior to single suicide gene therapy. The mechanism underlying the synergistic cytotoxicity of concom itant CD/5-FC and HSV-1 TK/GCV therapies is unclear, Note that the mean tumor volume of the trimodal therapy group never reached the predetermined end point of 400 mm 3 (even after 6 months). Thus, a statistical analysis of the average tumor growth delays comparing the trimodal therapy group with the other treatm ent groups could not be performed.
b The one animal in this group that was not tum or free 90 days posttreatment had a 60-mm 3 tumor and became tumor free at 6 months. a Note that the mean tumor volume of the Ad5-CD /TKrep 1 5-FC 1 GCV and trimodal therapy groups never reached the predeterm ined end point of 400 mmbut may stem from the fact that the two suicide gene systems target distinct, yet merging, biochemical pathw ays (Rogulski et al., 1997a) . As was shown here, double, but not single, suicide gene therapy can enhance significantly the antitumor effects of Ad5-CD/TKrep viral therapy. Independently, both the CD/5-FC and HSV-1 TK/GCV systems failed to improve the antitumor effects of the Ad5-CD/TKrep virus, despite their in vitro cytotoxicity. Low efficacy of the CD/5-FC system in vivo, despite in vitro potency, has been observed previously (Huber et al., 1993; Trinh et al., 1995; Kievit et al., 1999) and may be due to either inefficient conversion of the 5-FC substrate (Kievit et al., 1999) or a requirement for an intact host immune system (Consalvo et al., 1995) . The failure of the HSV-1 TK/GCV system to enhance the antitumor effects of the Ad5-CD/TKrep virus in the C33A model appears to stem from a balance between suicide gene-mediated cytotoxicity and suppression of viral replication. This antagonism may be tumor specific, as the HSV-1 TK/GCV system has been demonstrated to enhance the antitum or activity of a cytolytic virus in a colon xenograft (Wildner et al., 1999) . It should be noted, however, that a much higher dose (200 mg/kg/day) of GCV was used in that study, which is more than 3 times the dose used here and 10 times the dose that can be safely used in hum ans (15-20 mg/kg/day).
In both the subcutaneous and intramuscular tum or models, CD/5-FC and HSV-1 TK/GCV cotherapy achieved a potent antitumor effect in the context of the replication-com petent Ad5-CD/TKrep adenovirus, suggesting that the com bined cytotoxic effects outweigh the suicide gene-mediated antiviral effects (i.e., inhibition of viral replication and its accompanying cytolysis). Hence, despite the apparent ability of the suicide gene systems to interfere with Ad5-CD/TKrep viral replication, the therapeutic benefits of combining double suicide gene therapy with Ad5-CD/TKrep viral therapy are substantial. Because suicide gene therapy requires prodrug administration, maximal viral spread and tumor destruction can be allowed to occur prior to engaging the enzyme/prodrug systems (and radiation), thereby minimizing the deleterious effects of inhibiting viral replication.
Although the therapeutic benefits of coupling the CD/5-FC and HSV-1 TK/GCV enzyme/ prodrug system s and their use as a neoadjuvant to radiation therapy are well documented (Rogulski et al., 1997a,b; Aghi et al., 1998; Kim et al., 1998; Uckert et al., 1998; and this report) , an important issue not addressed here is the yet unproven benefit of using a replication-comp etent versus replication-defecti ve adenovirus to deliver the CD/HSV-1 TK fusion gene. Replication-com petent adenoviruses have several theoretical advantages over replication-defective viruses, some of which have been dem onstrated. As dem onstrated here, Ad5-CD/TKrep itself, via its cytolytic activity, results in a profound (20-45 days) tum or growth delay and 40% tumor cure. Similar tumor growth delays have been obtained in several other tumor models (subcutaneous DU145, 45 days; orthotopic LNCaP C4-2, 25 days). In contrast, the replication-defecti ve counterpart of Ad5-CD/TKrep, Ad5-FGNR, has demonstrated either little (C33A, 7 days) or no (Hep3B, SK-OV-3; Xie et al., 1999) tumor growth delay and no tumor cure in three tumor models. Second, as dem onstrated previously in vitro, replication-comp etent adenoviruses can result in markedly higher (up to 2000-fold) transgene expression per cell via their ability to achieve a high copy num ber , which, in turn, should result in greater conversion of prodrugs into their toxic metabolites. Third, replication-competent adenoviruses, via viral spread, have the potential to increase the in vivo gene transduction efficiency (percentage of tumor cells infected) relative to replication-defecti ve viruses. Whether the latter possibility holds true in vivo is presently unknown. Using the DU145 prostate adenocarcinoma model, we have found that Ad5-CD/TKrep viral therapy alone (10 8 PFU 3 5) results in a tumor growth delay (45 days) that is essentially equivalent to that (42 days) of the replication-defective Ad5-FGNR virus (10 8 PFU 3 5) and 14 days of double prodrug therapy (our unpublished results, 1999) . Consistent with our observations, Wildner and co-workers dem onstrated that a cytolytic HSV-1 TK-expressing adenovirus was as effective as a replication-defecti ve Ad.Tk vector and GCV prodrug therapy (Wildner et al., 1999) . The therapeutic efficacy of the cytolytic HSV-1 TK virus could be improved further with high doses of GCV. Cumulatively, these observations indicate that the potency of suicide gene therapy will be greater in the context of a replication-comp etent adenovirus than in a nonreplicating viral background.
Ad5-C D/TKrep is E1B attenuated and was modeled after ONYX-015 (Bischoff et al., 1996) , a virus originally hypothesized to target only tum ors of mutant p53 status by virtue of its inability to express the p53-inactivati ng 55-kD a E1B protein (Yew and Berk, 1992) . Much controversy has arisen regarding the selectivity of the E1B-attenuated adenoviruses Ornelles, 1997, 1998; Hall et al., 1998; Rothmann et al., 1998; Harada and Berk, 1999; Turnell et al., 1999) . Hall and colleagues dem onstrated that such viruses require wild-type p53 function for effective replication and cytolysis (Hall et al., 1998) . Our results, and those of others (Harada and Berk, 1999) , conflict dramatically with this tenet, as we have found that Ad5-CD /TKrep lyses efficiently tum or cells of both mutant (C33A , DU145, U251, HT-29) and wild-type (LNCaP, RKO, A549, U343) p53 status in vitro and our unpublished results, 1999) , and results in significant tumor growth delays with p53 wild-type (orthotopic LNCaP C4-2, 25 days) and mutant (C33A, 20-45 days; DU145, 45 days) tum ors. Nonetheless, our in vitro observations regarding the host range specificity of the E1B-attenuated adenoviruses do not agree well with the tenet originally put forth by ONYX (Bischoff et al., 1996) . Using isogenic tumor cell lines that express either wild-type (RKO, U343) or a dominant negative mutant (Arg-273 R His) of p53, we have observed reproducibly that the Ad5-CD /TKrep and ONYX-015 viruses replicate about three times faster in mutant p53 cells and that this can lead to slightly (two-to threefold) faster cytolysis in vitro (Rogulski et al., 1999) . Our observations agree well with the results of Berk and colleagues, who found, using a cell line expressing a temperature -sensitive mutant of p53, that the dl1520 (ONYX-015) virus replicates slower (, 3-fold) and yields a markedly lower viral burst when p53 is active (Harada and Berk, 1999) . Along these same lines, using the isogenic RKO/ RKOp53.13 tumor model (Slichenmy er et al., 1993) , we have found that ONYX-015 dem onstrates greater antitumor activity against mutant p53 tum ors. Specifically, intratumoral injection of ONYX-015 (10 8 PFU 3 5) resulted in a tum or growth delay with mutant p53 tumors (19 days) that was significantly better (p , 0.001) than with wild-type tumors (1 day) (Rogulski et al., 1999) . It is possible that the differential effect observed in vivo is related to the ability of the virus to replicate and, perhaps, spread faster in mutant p53 tumors. Whether this is universally true will require confirm ation in other isogenic tum or models.
Although conventional cancer therapies (surgery, chemotherapy, radiation therapy) are effective at curing early-stage disease, few hum an cancers are curable with a single modality. Without significant improvements in in vivo gene delivery, suicide gene therapy, as a monotherapy, will have limited value in the clinic. It has been our tenet that adenovirus-m ediated suicide gene therapy will show the most promise when used as a neoadjuvant to radiation therapy. Previously, we dem onstrated that both the CD/5-FC and HSV-1 TK/GCV systems could, independently, potentiate radiotherapy (Kim et al., 1994 (Kim et al., , 1995 (Kim et al., , 1997 Khil et al., 1996; Gable et al., 1998) . Even greater radiosensitization is achieved when both suicide gene systems are com bined (Rogulski et al., 1997a,b; Kim et al., 1998) . We have now extended these observations by demonstrating that double suicide gene therapy, in the context of a replication-comp etent adenovirus, can potentiate the therapeutic effects of radiation. Combining Ad5-CD /TKrep viral and radiotherapies, in the absence of double prodrug therapy, does not significantly improve tumor control beyond that of either monotherapy. In dramatic contrast, therapeutic outcom e is markedly improved when the suicide gene systems are engaged (trimodal therapy), even under conditions in which the suicide gene systems themselves produce no apparent chemotherapeuti c effect (i.e., 4 days of prodrug therapy). These results demonstrate clearly that the CD/5-FC and HSV-1 TK/GCV enzyme/prodrug systems can function as true radiosensitizers in vivo, improving therapeutic efficacy only through their synergistic interactions with radiation.
Because human adenoviruses do not replicate efficiently in mouse cells, human tum or xenografts in immunodeficie nt mice had to be used in these studies. It rem ains to be determined whether the dramatic results observed here can be achieved in an immunocom petent host (i.e., patients). It is presently unclear whether the host immune system will prove to be a "friend" (by generating an effective immune response to virally infected tumor cells) or "foe" (by preventing viral spread) of cancer therapies that utilize replication-com petent adenoviruses. The fact that the ONYX-015 virus has demonstrated antitumor activity in the clinic (Kirn et al., 1997) indicates that the immune system does not block the cytolytic action of replication-comp etent adenoviruses, at least with the initial dose. However, repeated doses appear to be less efficacious. Although the immune system may preclude extensive viral spread, it may not necessarily impede viral replication in infected cells. As described above, an advantage of using replication-comp etent adenoviruses as gene therapy vectors is their ability to achieve a high copy number resulting in significantly greater (up to 2000-fold; Freytag et al., 1998) therapeutic transgene expression per cell. Thus, even if the immune system precludes viral spread, replication-competen t vectors should still result in greater therapeutic gene expression per viral dose relative to replication-defective vectors. Moreover, although the immune system may attenuate the Ad5-CD/TKrep viral cytolytic effect, there is reason to believe that it will augment the efficacy of CD/5-FC and HSV-1 TK/GCV suicide gene therapies (Vile et al., 1994; Consalvo et al., 1995) . Thus, the efficacy of the combined therapy described here may depend on whether the antitumor effects of host immune system (immune response to virally infected cells and augmentation of suicide gene therapies) outweigh its negative effects on viral spread. The merit of this combined approach is best evaluated in the clinic, which will commence in 1999.
